Difference between revisions of "Penpulimab (Anniko)"

Latest revision as of 13:00, 8 September 2023

PD-1 inhibitor

2021-08-05: Initial approval for treatment of patients with relapsed or refractory ("r/r") classic Hodgkin’s lymphoma ("cHL") after at least second-line systemic chemotherapy treatment.
2023-01-15: Approved in combination with chemotherapy as the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC). (Based on AK105-302)

@@ Line 1: / Line 1: @@
-'''Note: Penpulimab is approved in China, but does not appear to have a brand name at this time.'''
 ==Mechanism of action==
 PD-1 inhibitor
 ==Diseases for which it is used==
-*[[Hodgkin lymphoma]]
+*[[Classical Hodgkin lymphoma]]
+*[[Non-small cell lung cancer, squamous]]
 ==History of changes in NMPA indication==
-*2021-08-05: Approved for treatment of patients with relapsed or refractory ("r/r") [[Hodgkin lymphoma|classic Hodgkin’s lymphoma ("cHL")]] after at least second-line systemic chemotherapy treatment.
+*2021-08-05: Initial approval for treatment of patients with relapsed or refractory ("r/r") [[Classical Hodgkin lymphoma|classic Hodgkin’s lymphoma ("cHL")]] after at least second-line systemic chemotherapy treatment.
+*2023-01-15: Approved in combination with chemotherapy as the first-line treatment of locally advanced or metastatic [[Non-small cell lung cancer, squamous|squamous non-small cell lung cancer (sq-NSCLC)]]. ''(Based on AK105-302)''
 ==Also known as==
-*'''Code name:''' AK105
+*'''Code name:''' AK-105
+*'''Generic name:''' pianprizumab
+*'''Brand name:''' Anniko, Annikol
 [[Category:Drugs]]
@@ Line 16: / Line 19: @@
 [[Category:Anti-PD-1 antibodies]]
-[[Category:Hodgkin lymphoma medications]]
+[[Category:Classical Hodgkin lymphoma medications]]
-[[Category:NMPA approved drugs]]
+[[Category:Non-small cell lung cancer, squamous medications]]
+[[Category:NMPA approved in 2021]]